Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands upon a working relationship between the two companies that began in 2014, during which Cheplapharm had previously acquired portions of Sanofi’s mature medicines portfolio. The selected medicines, which include Lovenox and Clexane (enoxaparin), are intended to benefit from Cheplapharm’s operational approach. Both companies stated that distinct operating models may be better suited to address the specific manufacturing, regulatory, and commercial characteristics of established treatments compared to those required for novel drug development.
Global Manufacturing Transition
Cheplapharm will take over production sites located in Csanyikvölgy in Hungary, Jurong in Singapore, and Ploërmel in France. These facilities currently employ approximately 400, 100, and 65 employees, respectively. Both entities have stated that existing employment terms and collective agreements are expected to remain in place. The companies plan to jointly manage the transition, with a primary focus on maintaining supply continuity and upholding manufacturing standards throughout the handover process.
Thomas Grenier, Executive Vice President of Sanofi General Medicines, noted that the multi-year journey to simplify the mature portfolio has enabled Sanofi to focus on innovation. He emphasized that Cheplapharm has been a trusted partner for more than a decade, and this transaction significantly builds on prior acquisitions. “This new partnership, together with our equity stake in Cheplapharm, underscores our commitment to ensuring patients continue to benefit from today’s essential medicines while also pursuing tomorrow’s breakthroughs,” Grenier said.
Regulatory and Commercial Timeline
The planned commercial transition is targeted to begin in the first quarter of 2027, with full completion anticipated by the third quarter of 2027. This timeline is subject to receiving necessary regulatory approvals and completing employee consultations. Sanofi indicated that the transaction is not expected to affect its financial guidance for 2026, although further financial details regarding the specific terms of the divestiture have not yet been disclosed.
Separately from this divestiture, Sanofi’s Hungarian operations are currently facing scrutiny regarding competition practices. Sanofi-Aventis, along with Opella Healthcare Commercial, Haleon Hungary, wholesaler Phoenix Pharma, and pharmacy chain operator Benu Magyarország, are being investigated in Hungary to determine whether they have been restricting competition in the over-the-counter drug market. This regulatory probe highlights the broader compliance environment in which the company operates as it restructures its global portfolio.
Recent regulatory developments for Sanofi have also included the approval by Japan’s Ministry of Health, Labour and Welfare in June for its subcutaneous formulation of Sarclisa (isatuximab). This approval allows the drug to be used in combination with standard therapies to treat multiple myeloma. As Sanofi transitions its mature portfolio to Cheplapharm, the company continues to pursue approvals for its newer therapeutic candidates in international markets.
The shift of established medicines to a specialized partner reflects a growing trend in the pharmaceutical industry, where large biopharmaceutical companies are increasingly separating their legacy portfolios from their innovative pipelines. By transferring these assets, Sanofi aims to optimize its operational efficiency while leveraging Cheplapharm’s expertise in managing the lifecycle of established drugs. The completion of this transfer in 2027 will mark a significant step in the restructuring of Sanofi’s global manufacturing and commercial footprint.
